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Do viruses require the cytoskeleton?
Jason D Matthews, Rachel Morgan, Christie Sleigher and Teryl K Frey*

Abstract
Background: It is generally thought that viruses require the cytoskeleton during their replication cycle. However,
recent experiments in our laboratory with rubella virus, a member of the family Togaviridae (genus rubivirus),
revealed that replication proceeded in the presence of drugs that inhibit microtubules. This study was done to
expand on this observation.
Findings: The replication of three diverse viruses, Sindbis virus (SINV; family Togaviridae family), vesicular stomatitis
virus (VSV; family Rhabdoviridae), and Herpes simplex virus (family Herpesviridae), was quantified by the titer (plaque
forming units/ml; pfu/ml) produced in cells treated with one of three anti-microtubule drugs (colchicine, noscapine,
or paclitaxel) or the anti-actin filament drug, cytochalasin D. None of these drugs affected the replication these
viruses. Specific steps in the SINV infection cycle were examined during drug treatment to determine if alterations
in specific steps in the virus replication cycle in the absence of a functional cytoskeletal system could be detected,
i.e. redistribution of viral proteins and replication complexes or increases/decreases in their abundance. These
investigations revealed that the observable impacts were a colchicine-mediated fragmentation of the Golgi
apparatus and concomitant intracellular redistribution of the virion structural proteins, along with a reduction in
viral genome and sub-genome RNA levels, but not double-stranded RNA or protein levels.
Conclusions: The failure of poisons affecting the cytoskeleton to inhibit the replication of a diverse set of viruses
strongly suggests that viruses do not require a functional cytoskeletal system for replication, either because they do
not utilize it or are able to utilize alternate pathways when it is not available.
Keywords: Virus replication, Cytoskeleton, Microtubules, Actin filaments

Findings
There are three major components to the cytoskeleton;
actin filaments [1], intermediate filaments [2], and microtubules [3], which in toto are necessary for maintenance of
cell shape, cell motility and intracellular transport. It is
generally thought that viruses require the cytoskeleton
during infection [4], although a review of the literature
reveals that most studies analyze the requirement of the
cytoskeleton for specific steps in the viral replication cycle
rather than the complete replication cycle. Recently, in
such a study on the effects of anti-microtubule drugs on
the formation of cytoplasmic fibers by a replicase protein
of rubella virus, to our surprise we found that these drugs
did not significantly affect the titer of virus produced [5].
To see if this finding held for other viruses, we tested the

replication of three diverse viruses (Table 1) against the
same panel of anti-microtubule drugs (Table 2) and also
included the anti-actin filament drug, cytochalasin D.
BHK (baby hamster kidney) cells (ATCC) were treated
with different cytoskeletal drugs one hour after the cells
were infected, and the drugs remained on the cells for the
24 hour time course of the experiment. Infection was
done at a low multiplicity of infection (MOI; 0.1 pfu/cell
for SINV and VSV, 0.01 pfu/cell for HSV) to ensure that
multiple rounds of infection occurred, thus subjecting
every step in the virus replication cycle to the presence of
the drugs. Each of these viruses replicates rapidly ensuring
that replication was complete during the time course of
the experiment. Media harvested from untreated control
or drug-treated infected BHK cells at 24 hours postinfection was titered by plaque assay to determine viral
yields. None of the viruses tested exhibited a reduction in

* Correspondence: tfrey@gsu.edu
Department of Biology, Georgia State University, Atlanta, GA, USA
© 2013 Matthews et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Matthews et al. Virology Journal 2013, 10:121
http://www.virologyj.com/content/10/1/121

Page 2 of 5

Table 1 Viruses used in this study
Virus

Genome

Family

Genus

Host

Site of replication

Herpes simplex virus (HSV-1)

dsDNA

Herpesviridae

Simplexvirus

Human

Nucleus

Sindbis virus (SINV)

(+)ssRNA

Togaviridae

Alphavirus

Vertebrates; Mosquitoes

Cytoplasm

Vesicular stomatitis virus (VSV)

(−)ssRNA

Rhabdoviridae

Vesiculovirus

Vertebrates; Arthropods

Cytoplasm

Table 2 Drugs used in this study
Drug

Source

Mode of action

Clinical use

Colchicine

Colchicum
autmnale

Depolymerizes
microtubules

Gout treatment

Noscapine

Plants of the
Papaveraceae
family

Inhibits microtubule
dynamics

Cough
suppressant

Paclitaxol

Taxus brevifolia

Inhibits mitosis by
stabilizing
microtubules

Anti-cancer
therapy

Cytochalasin D

Zygosporium
mansonii

Depolymerizes actin
filaments

None

A
9

7

Log10 pfu/ml

yield in cells treated with any of the anti-cytoskeleton
drugs (Figure 1A), indicating that these viruses do not
need a functioning cytoskeletal system to complete their
replication cycle. The replication of VSV was tested at
additional MOI’s (10 and 1 pfu/cell) with the same result
(Figure 1B). We also compared the replication curves of
VSV during drug treatments to the curves of untreated
controls, all of which were infected at an MOI of 0.1 pfu/
cell with a time-course of virus yield at 6, 12 and 24 hours
post-infection. There were no differences in the growth
kinetics for VSV between untreated or treated cultures
during the time-course (data not shown).
Given our finding that three diverse viruses replicate to
similar titers in the absence or presence of anti-cytoskeletal
drugs, we hypothesized that either these viruses do not
need the cytoskeletal system or use alternate pathways
when it is not available. Since these hypotheses could apply
differentially to the steps in the virus replication cycle, we
used SINV to investigate whether the anti-cytoskeleton
drugs had effects on specific steps in the virus replication
cycle. SINV produces four nonstructural proteins (nsP1-4)
that are involved in RNA-dependent RNA synthesis occurring in membranous structures in the cytoplasm of
infected cells [6-8]. Using a recombinant SINV expressing
a GFP-tagged nsP3 (described in [9]), we found that without drug treatment nsP3-GFP localized in perinuclear foci
distributed in the cytoplasm of SINV/NSP3-GFP-infected
cells (consistent with previous reports [9]) and changed
little under treatment with the cytoskeletal drugs (Figure 2A and B). SINV produces three structural proteins that
comprise the virus particle, the capsid protein C and envelope glycoproteins E1 and E2 [10], which is formed by
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Figure 1 Effect of cytoskeletal drug treatments on virus
replication. A). BHK cells were infected for 1 hour at 35°C with
either Herpes Simplex virus-1 (HSV-1; multiplicity of infection (MOI) = 0.01
plaque forming unit (pfu)/cell), Sindbis virus (SINV; MOI = 0.1 pfu/cell) or
vesicular stomatitis virus (VSV; MOI = 0.1 pfu/cell) and then incubated at
35°C in medium with the indicated drug. The minimal concentrations
necessary to inhibit the appropriate cytoskeletal system were used as
determined either by immunofluorescence staining of drug-treated,
uninfected BHK cells, using antibodies against the microtubules or by
phalloidin-Alexa Fluor 568 staining which binds to actin filaments, to
observe changes in cytoskeletal morphology and/or inhibition of mitosis
(the effects these poisons have on cells). At 24 hours post-infection, the
cell culture fluid was harvested and titered by plaque assay. Results,
given in log10 PFU/mL, were the average of three independent
experiments. Error bars represent the standard deviation from the mean.
B). BHK cells were infected for 1 hour at 4°C with VSV at MOI’s of 0.1, 1,
or 10 pfu/cell. Subsequently, the cells were incubated at 35°C in medium
with the indicated drug. At 24 hours post-infection, the cell culture fluid
was harvested and titered by plaque assay. The results were the average
of two independent experiments. Error bars represent the standard
deviation from the mean.
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Figure 2 Analysis of SINV replication during cytoskeletal drug treatment. A and B. BHK cells infected at an MOI = 1 for 1 hour with SINV
expressing an nsP3-GFP fusion protein (green), called SINV/NSP3-GFP, before treating the infected cells with the appropriate cytoskeletal drug for
5 hours. At 6 hours post-infection, the infected cells were stained for fluorescence microscopy with rabbit anti-microtubule antibodies (secondary
antibody was donkey anti-rabbit AlexaFluor 595), the F-actin filaments with phalloidin AlexaFluor 568-conjugate (A), or staining for the structural
proteins with rabbit antibodies raised against purified virus (visualized by donkey anti-rabbit Alexa Fluor 595-conjugate) (B). Insets in B (red), show
localization of structural proteins. NT, no treatment. Nuclei were stained with Hoechst 33342 (blue). Bars represent 10 μm. White arrows point to
juxtanuclear foci of structural proteins, blue arrow points to scattered structural protein foci. C. BHK cells infected with SINV (MOI = 1 pfu/cell) for
1 hour and then incubated with medium or medium containing 30 μM colchicine for an additional 5 hours were treated with a Golgi stain
(wheat germ agglutinin Alexa Fluor 595 conjugate, red) along with antibodies against SINV structural proteins that were visualized with antirabbit FITC conjugate (green) to localize the structural proteins. Nuclei were stained with Hoechst 33342 (blue). Bars represent 20 μm. White
arrows point to structural protein overlap with the Golgi. Yellow arrows point to fragmented, but overlapping, Golgi and structural proteins.
D. Western blotting of SINV-infected (MOI = 1 pfu/cell) BHK cell lysates prepared as in A. Calnexin serves as a loading control. NSP2 was detected
with rabbit anti-NSP2 antibody. The structural proteins, E1, pE2 and E2 were detected with rabbit polyclonal antibodies. pE2 and E2 proteins were
detected with cdE2 antibodies. Protein bands were visualized with the species-specific alkaline phosphatase-conjugated antibodies and
substrate NBT/BCIP.

budding of the nucleocapsid containing C and the genome
RNA, through the plasma membrane. The intracellular
distribution of the structural proteins was examined by
staining with polyclonal antibodies raised in rabbits against
purified SINV. Consistent with previous reports, the

structural proteins were found throughout the cytoplasm
of infected cells and were particularly concentrated in the
perinuclear region (Figure 2B) in what has been shown to
be the Golgi apparatus [11]. Neither noscapine or paclitaxel disrupted the overall distribution of the structural
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proteins as a whole, however colchicine disrupted the perinuclear localization of the structural proteins into
fragmented foci that appeared scattered in the cytoplasm.
The cytochalasin-D disrupted the shape of the infected
cells making analysis of the structural protein signal difficult to localize, however they did appear to remain concentrated in the perinuclear region.
Since colchicine has previously been shown to disrupt
the Golgi [12], wheat germ agglutinin Alexa Fluor 594
conjugate was used to stain the Golgi. In untreated,
SINV-infected BHK cells, the structural proteins’ signal
concentrated in the perinuclear region overlapping with
the Golgi signal (Figure 2C). However, the Golgi appeared
fragmented or was absent in the colchicine-treated cells,
but the structural protein signal still overlapped many of
the fragmented Golgi foci. Western blotting of lysates
from SINV-infected cells probed with anti-nsP2 or antistructural protein antibodies revealed that viral protein
synthesis was not significantly affected by colchicine,
albeit with a minor decrease in levels, particularly of E2,
but not of its precursor pE2 (Figure 2D). No obvious
changes were observed in dsRNA distribution or abundance (a marker for sites of RNA-dependent RNA synthesis) in colchicine-treated vs untreated cells except for
more staining of dsRNA around the edges of the untreated cells (Figure 3A). In contrast, Northern blotting
analysis showed somewhat lower levels of SINV genome
and subgenome RNA in the colchicine-treated cells than
in the control cells (Figure 3B).
In summary, following studies in our lab with rubella
virus [5] which found that its replication was not
inhibited by four anti-microtubule drugs, we decided to
test the hypothesis that viruses can replicate in the presence of drugs which compromise the cytoskeletal system
by broadening our study to include another positivestrand RNA virus, a negative-strand RNA virus, and a
DNA virus. Our findings demonstrate that viruses can
produce normal titers in the absence of a functional
cytoskeletal system, (similar results were reported for
SINV in another lab [7]) which challenges the currently
accepted notion [4]. In this regard, it was shown that
poliovirus can complete its entire infection cycle in a
cell-free system lacking a cytoskeleton system [13]. To
address the alternate hypotheses of whether viruses simply do not need the cytoskeletal system or use alternate
pathways when it is not available, we investigated the
replication cycle of SINV in the presence of the anticytoskeletal drugs in more detail. No obvious changes
occurred to any of the stages of SINV infection in the
presence of noscapine, paclitaxel, and cytochalasin D.
However, the Golgi through which the SINV envelope
glycoproteins mature during transport to the plasma
membrane, was severely compromised by colchicine,
concomitantly affecting the distribution of the SINV
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Figure 3 RNA synthesis in SINV-infected cells after colchicine
treatment. A. Localization of dsRNA complexes after colchicine
treatment. SINV/NSP3-GFP-infected BHK cells (MOI = 1 pfu/cell),
untreated or treated with colchicine from 1–6 hours post-infection
were stained at 6 hours post-infection with mouse anti-dsRNA
antibodies (Scientific Consultants) and visualized with donkey antimouse Alexa Fluor 595 secondary antibodies (red). Nuclei are stained
with Hoechst 33342 (blue) and bars represent 10 μm. B. Northern
blotting of lysates of SINV-infected BHK cells (MOI = 1 pfu/cell) after
no treatment or treatment with 30 μM colchicine (from 1–24 hours
post-infection) prepared at 24 hours post-infection. SINV-specific
RNAs were detected by probing with a 32P probe labeled by nicktranslation of a plasmid containing the SINV structural protein genes.

structural proteins. It will be of interest to study the effect of colchicine treatment on maturation and transport
of these SINV proteins to see if an alternate pathway exists that the virus uses in this step of its replication cycle
in the presence of this drug.
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